

FMHL/SE/ NOV'23

November 6, 2023

BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001
Scrip Code: 523696

Subject: Outcome of the Board Meeting.

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosures Requirement) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. November 6, 2023, *inter-alia*, considered and approved unaudited standalone and consolidated financial results of the Company for the quarter and period ended September 30, 2023.

Accordingly, please find enclosed standalone and consolidated un-audited financial results along with statement of assets and liabilities, cash flow statement and limited review report given by the Statutory Auditor of the Company for the quarter and period ended on September 30, 2023.

The Board Meeting commenced at 1300 Hours and concluded at 1615 Hours.

Please find enclosed Quarterly Results along with limited review reports thereon.

This is for your information and record please.

Thanking You
For **Fortis Malar Hospitals Limited**



Sandeep Singh
Company Secretary & Compliance Officer
Membership No.: F9877

Encl.: as above

STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30-SEPTEMBER-2023

(Rs. in lakhs except equity share data)

No.	Particulars	Standalone Quarter ended			Standalone Half year ended		Standalone Year ended	Consolidated Quarter ended			Consolidated Half year ended		Consolidated Year ended
		30-Sept-2023	30-June-2023	30-Sept-2022	30-Sept-2023	30-Sept-2022	31-Mar-2023	30-Sept-2023	30-June-2023	30-Sept-2022	30-Sept-2023	30-Sept-2022	31-Mar-2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income												
	a) Revenue from operations	1,814.91	1,776.07	2,329.43	3,590.98	4,339.17	8,595.08	1,814.91	1,776.07	2,329.43	3,590.98	4,339.17	8,595.08
	b) Other income	229.21	159.09	148.82	388.30	311.05	655.78	231.26	161.10	150.47	392.36	314.24	663.81
	Total income	2,044.12	1,935.16	2,478.25	3,979.28	4,650.22	9,250.86	2,046.17	1,937.17	2,479.90	3,983.34	4,653.41	9,258.89
2	Expenses												
	a) Purchase of medical consumables and drugs	232.15	243.76	310.20	475.91	619.36	1,190.47	232.15	243.76	310.20	475.91	619.36	1,190.47
	b) Changes in inventories of medical consumables and drugs	2.19	(11.12)	49.04	(8.93)	63.48	76.02	2.19	(11.12)	49.04	(8.93)	63.48	76.02
	c) Employee benefits expense	428.56	486.51	462.45	915.07	952.34	1,933.27	430.45	488.40	464.25	918.85	955.94	1,940.57
	d) Finance costs	129.99	134.99	160.85	264.98	315.95	607.06	129.99	134.99	160.85	264.98	315.95	607.06
	e) Professional charges / consultation fees to doctors	555.51	543.33	627.43	1,098.84	1,236.01	2,487.25	553.33	541.16	625.36	1,094.49	1,231.87	2,478.97
	f) Clinical establishment fees	135.83	132.72	177.46	268.55	328.22	643.61	135.83	132.72	177.46	268.55	328.22	643.61
	g) Depreciation and amortization expenses	271.58	267.18	290.55	538.76	592.49	1,214.66	271.58	267.18	290.55	538.76	592.49	1,214.66
	h) Other expenses	469.05	431.82	474.91	900.87	914.25	1,806.27	469.52	432.52	475.30	902.04	915.16	1,808.32
	Total expenses	2,224.86	2,229.19	2,552.89	4,454.05	5,022.10	9,958.61	2,225.04	2,229.61	2,553.01	4,454.65	5,022.47	9,959.68
3	Loss before tax (1-2)	(180.74)	(294.03)	(74.64)	(474.77)	(371.88)	(707.75)	(178.87)	(292.44)	(73.11)	(471.31)	(369.06)	(700.79)
4	Tax expense	-	-	364.42	-	364.42	845.57	0.47	0.40	364.81	0.87	365.13	847.32
	- Current tax	-	-	-	-	-	-	0.49	0.40	0.40	0.89	0.73	1.81
	- Deferred tax charged/ (credit)	-	-	364.42	-	364.42	845.57	(0.02)	-	364.41	(0.02)	364.40	845.51
5	Loss after tax (3-4)	(180.74)	(294.03)	(439.06)	(474.77)	(736.30)	(1,553.32)	(179.34)	(292.84)	(437.92)	(472.18)	(734.19)	(1,548.11)
	Other comprehensive income / (loss) (net of tax)												
	Items that will not be reclassified subsequently to the statement of profit and loss:												
	(a) Remeasurements of defined benefit liability	(2.97)	(9.64)	10.72	(12.61)	27.35	(47.94)	(2.97)	(9.64)	10.72	(12.61)	27.35	(47.75)
	(b) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	(0.05)
6	Other comprehensive income / (loss) (net of tax)	(2.97)	(9.64)	10.72	(12.61)	27.35	(47.94)	(2.97)	(9.64)	10.72	(12.61)	27.35	(47.80)
7	Total comprehensive loss for the period / year (5+6)	(183.71)	(303.67)	(428.34)	(487.38)	(708.95)	(1,601.26)	(182.31)	(302.48)	(427.20)	(484.79)	(706.84)	(1,595.91)
	Total comprehensive loss attributable to:												
	- Owners of the company	NA	NA	NA	NA	NA	NA	(182.31)	(302.48)	(427.20)	(484.79)	(706.84)	(1,595.91)
	- Non-controlling interests	NA	NA	NA	NA	NA	NA	-	-	-	-	-	-
8	Paid up equity share capital (face value Rs.10 each)	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70
9	Reserves excluding revaluation reserves - other equity	NA	NA	NA	NA	NA	4,320.04	NA	NA	NA	NA	NA	4,541.54
10	Earnings Per Share (EPS) based on (5) above (of Rs. 10 each) - (Not annualised in the quarters and half year)												
	- Basic	(0.96)	(1.57)	(2.34)	(2.53)	(3.93)	(8.29)	(0.96)	(1.56)	(2.34)	(2.52)	(3.92)	(8.26)
	- Diluted	(0.96)	(1.57)	(2.34)	(2.53)	(3.93)	(8.29)	(0.96)	(1.56)	(2.34)	(2.52)	(3.92)	(8.26)



Chandrasekar R

FORTIS MALAR HOSPITALS LIMITED (CIN: L85110PB1989PLC045948)

Regd. Office: Fortis Hospital, Sector 62, Phase – VIII, Mohali-160062

Tel Numbers: 0172 5096001 & Tele Fax No : 0172 5096002

Website: www.fortismalar.com; Email: secretarial.malar@malarhospitals.in

STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIXTH MONTHS ENDED 30-SEPTEMBER-2023

Notes:

1. STANDALONE AND CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

(Rs. in lakhs)

Particulars	Standalone		Consolidated	
	As at 30-Sept-2023	As at 31-Mar-2023	As at 30-Sept-2023	As at 31-Mar-2023
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
ASSETS				
Non-current assets				
Property, plant and equipment	1,250.61	1,147.48	1,250.61	1,147.48
Right of use assets	3,166.59	3,576.45	3,166.59	3,576.45
Other Intangible assets	14.62	17.25	14.62	17.25
Intangible assets under development	5.86	-	5.86	-
Financial assets				
Investment in subsidiary	5.00	5.00	-	-
Other financial assets	45.11	45.64	45.11	45.64
Deferred tax assets (net)	-	-	0.51	0.49
Other tax assets (net)	690.43	541.80	712.47	563.05
Other non-current assets	2.46	2.11	2.46	2.11
Total non-current assets	5,180.68	5,335.73	5,198.23	5,352.47
Current assets				
Inventories	119.27	110.34	119.27	110.34
Financial assets				
Trade receivables	251.40	318.44	251.40	318.44
Cash and cash equivalents	342.39	372.97	558.94	586.07
Bank balances other than (ii) above	2,417.70	357.65	2,417.70	357.65
Loans	4,000.00	6,800.00	4,000.00	6,800.00
Other financial assets	202.04	199.24	203.40	200.27
Other current assets	103.58	74.75	103.58	74.75
Total current assets	7,436.38	8,233.39	7,654.29	8,447.52
Total assets	12,617.06	13,569.12	12,852.52	13,799.99
EQUITY AND LIABILITIES				
Equity				
Equity share capital	1,875.70	1,875.70	1,875.70	1,875.70
Other equity	3,832.66	4,320.04	4,056.75	4,541.54
Total equity	5,708.36	6,195.74	5,932.45	6,417.24
Liabilities				
Non-current liabilities				
Financial liabilities				
Lease liabilities	3,353.88	3,818.14	3,353.88	3,818.14
Provisions	472.99	387.81	474.34	389.09
Total non-current liabilities	3,826.87	4,205.95	3,828.22	4,207.23
Current liabilities				
Financial liabilities				
Lease liabilities	886.54	821.62	886.54	821.62
Trade payables				
Total outstanding dues of micro enterprises and small enterprises	26.10	34.41	26.10	34.41
Total outstanding dues of creditors other than micro enterprises and small enterprises	1,778.57	1,991.12	1,777.71	1,992.91
Other financial liabilities	101.96	23.62	101.96	23.62
Provisions	38.85	80.09	39.52	80.76
Current tax liabilities (net)	-	-	1.20	0.33
Other current liabilities	249.81	216.57	258.82	221.87
Total current liabilities	3,081.83	3,167.43	3,091.85	3,175.52
Total liabilities	6,908.70	7,373.38	6,920.07	7,382.75
Total equity and liabilities	12,617.06	13,569.12	12,852.52	13,799.99

Page 2 of 4



Chandrasekar

FORTIS MALAR HOSPITALS LIMITED (CIN: L85110PB1989PLC045948)

Regd. Office: Fortis Hospital, Sector 62, Phase – VIII, Mohali-160062

Tel Numbers: 0172 5096001 & Tele Fax No : 0172 5096002

Website: www.fortismalar.com; Email: secretarial.malar@malarhospitals.in

STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30-SEPTEMBER-2023

Notes:

2. STANDALONE AND CONSOLIDATED STATEMENT OF CASH FLOWS

(Rs. in lakhs)

Particulars	Standalone		Consolidated	
	Half Year ended 30 September 2023	Half Year ended 30 September 2022	Half Year ended 30 September 2023	Half Year ended 30 September 2022
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Cash flows from operating activities				
Loss before tax for the year	(474.77)	(371.88)	(471.30)	(369.06)
<i>Adjustments for:</i>				
Interest income	(264.77)	(311.05)	(268.83)	(314.24)
Depreciation and amortisation expense	538.76	592.49	538.76	592.49
Interest expense on lease liability	251.60	291.34	251.60	291.34
Allowance for credit losses (including bad debts written off)	52.51	18.62	52.51	18.62
Liabilities no longer required written back	(123.53)	-	(123.53)	-
Operating profit before working capital changes	(20.20)	219.52	(20.79)	219.15
<i>Movements in working capital:</i>				
(Increase) / decrease in other current and non current financial assets	(37.19)	40.81	(37.19)	40.46
(Increase) in other current and non-current assets	(29.18)	(2.63)	(29.18)	(2.63)
Decrease / (increase) in trade and other receivables	14.53	(111.63)	14.53	(111.63)
(Increase) / decrease in inventories	(8.93)	63.48	(8.93)	63.48
Increase in provisions	31.33	22.75	31.40	22.81
(Decrease) / increase in trade payables	(97.34)	424.08	(99.98)	423.56
Increase / (decrease) in other current liabilities	33.24	(11.87)	36.94	(10.56)
Cash (used in) / generated from operations	(113.74)	644.51	(113.20)	644.64
Income taxes (paid) / refund received (net)	(148.63)	49.60	(148.72)	49.64
Net cash (used in) / generated from operating activities (A)	(262.37)	694.11	(261.92)	694.28
Cash flows from investing activities				
Payments for purchase of property, plant and equipment, intangible assets, capital work-in-progress and intangible assets under development	(156.92)	(139.30)	(156.92)	(139.30)
Inter-corporate deposit repaid by related parties	2,800.00	-	2,800.00	-
Bank balances not considered as cash and cash equivalents	(2,060.05)	(324.81)	(2,060.05)	(324.81)
Interest received	299.69	274.13	302.69	276.97
Net cash generated from / (used in) investing activities (B)	882.72	(189.98)	885.72	(187.14)
Cash flows from financing activities				
Repayment of lease liabilities including interest thereon	(650.93)	(632.59)	(650.93)	(632.59)
Net cash used in financing activities (C)	(650.93)	(632.59)	(650.93)	(632.59)
Net decrease in cash and cash equivalents (A+B+C)	(30.58)	(128.46)	(27.13)	(125.45)
Cash and cash equivalents at the beginning of the period	372.97	1,033.47	586.07	1,240.29
Cash and cash equivalents at the end of the period	342.39	905.01	558.94	1,114.84



Chandrasekar R

FORTIS MALAR HOSPITALS LIMITED (CIN: L85110PB1989PLC045948)

Regd. Office: Fortis Hospital, Sector 62, Phase – VIII, Mohali-160062

Tel Numbers: 0172 5096001 & Tele Fax No : 0172 5096002

Website: www.fortismalar.com; Email: secretarial.malar@malarhospitals.in

STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30-SEPTEMBER-2023

Notes:

- 3 The unaudited standalone and consolidated financial results for the quarter and six months ended 30 September 2023 has been reviewed by the Audit and Risk Management Committee and subsequently approved by the Board of Directors at their respective meeting held on 6 November 2023. The above results have been subjected to limited review by the Statutory auditors of the Company. The auditors have issued an unmodified review report.
- 4 These unaudited financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 5 The consolidated financial results includes the financial results of the Company Fortis Malar Hospitals Limited and the financial results of its subsidiary company Malar Stars Medicare Limited (collectively known as "Group").
- 6 The Company is engaged in the Healthcare Services, which in the context of Indian Accounting Standard (Ind AS) 108 - Operating Segments is considered as the only reportable segment of the Company.
- 7 Request for regularization of the hospital building in which the Company operates was made vide an application dated 29th May 1999 to Chennai Metropolitan Development Authority ("CMDA"). In the year 2012, Land and hospital building was sold by the Company to Fortis Health Management Limited ("FHML"). Company and FHML had also simultaneously entered into a "Hospital and Medical Services Agreement" w.r.t. rendering of medical and healthcare services in the hospital premises (including right to use of the hospital building). CMDA by its Order dated 18th March 2016 ("Rejection Order") rejected the regularization application that was submitted in the year 1999. A statutory appeal was preferred in April 2016 before the Secretary to the Government of Tamil Nadu, Housing and Urban Development Authority ("Authority") challenging the said Rejection Order. During the pendency of the statutory appeal, on 3rd May 2016, CMDA served a "Lock & Seal" Notice stating that in view of the Rejection Order, construction at the site of the Hospital premises is unauthorized and called upon to restore the land to its original state within 30 days from the date of the Notice. A writ petition was filed before the Hon'ble High Court of Judicature at Madras which set aside the "Lock & Seal" Notice and ordered that no coercive steps should be taken by CMDA, till disposal of the statutory appeal. The said appeal is still subjudice.

At the request of the Company, CMDA inspected the hospital building and issued a letter dated 25th August 2020, wherein certain clearances and certificates were sought within 30 days in connection with the regularization. In this regard, an extension of time was sought in November 2020. Simultaneously, actions were initiated for collating/obtaining requisitioned clearances and certificates which involved taking number of actions, significant expenses and capital expenditure. During the pandemic, there were lockdowns resulting in limited and restricted access to various offices all across, which slowed down the progress of actions initiated. The Company continued to undertake bonafide steps on best effort basis to complete the process of submission of the clearances and certificates sought by CMDA. On 20th May 2021, an update was sent to CMDA confirming that out of six requirements, as set out in their letter dated 25th August 2020, three have already been complied with and steps were underway for completion of the remaining actions. Subsequently, the Company obtained NOC from the Airport Authority of India dated 24th February 2022. Thereafter, for regularisation of the building, on 7th June 2022, an application along with available documents were submitted with CMDA. For processing the said application accompanied with available documents in support of Company's claim for regularisation, requisite scrutiny fee was deposited. The Company has been taking bonafide steps for issuance of fire compliance certificate and has been recently advised by the concerned authority to undertake certain steps and thereafter apply for the same. Having said this, steps as indicated, are being evaluated for further action and in the meanwhile it is being ensured that requisite safety measures are in place in the hospital building. In connection with this, a writ petition was filed before Hon'ble High Court of Judicature at Madras by FHML against Bharat Petroleum Corporation Limited (BPCL) and others for seeking possession of the land adjacent to the hospital premises. On 11th August 2023, the Hon'ble High Court has directed BPCL to hand over peaceful and vacant possession of premises to FHML within a period of three months. The Hon'ble Court has also directed the local Authorities to cancel the NOC/ License under the Explosives Act issued to BPCL/ its Franchisee upon expiry of three months. While the Company is co-operating to get all the clearance, based on legal advice, Company is of the view that it is not required to bear any expenses, revenue or capital in nature, incurred towards regularization of building and for obtaining requisite clearances and certificates (or for the expenses that may be incurred in the unlikely event that the regularization is not approved) as all such expenses will be borne by FHML. The Company continues to believe that all Orders / Notices issued by CMDA prima facie would not result in any significant adverse impact on its financial statements or on the going concern status.

8 Figures for the prior periods / year have been reclassified/ regrouped wherever required to conform to the classification of the current periods / year.

9 These financial results are available on the BSE website (www.bseindia.com) and on the Company's website (www.fortismalar.com)



By Order of the Board
Fortis Malar Hospitals Limited
CIN: L85110PB1989PLC045948

Chandrasekar R
Chandrasekar R
Whole Time Director
DIN : 09414564

Place : Chennai
Date: 06 November 2023

Limited Review Report on unaudited standalone financial results of Fortis Malar Hospitals Limited for the quarter ended 30 September 2023 and year to date results for the period from 01 April 2023 to 30 September 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Fortis Malar Hospitals Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Fortis Malar Hospitals Limited (hereinafter referred to as "the Company") for the quarter ended 30 September 2023 and year to date results for the period from 01 April 2023 to 30 September 2023 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We draw attention to Note 7 to the standalone financial results which describes the litigation and issues pertaining to regularization of the hospital building in which the Company operates today and the related matters. A letter was received from Chennai Metropolitan Development Authority (CMDA) on 25 August 2020, wherein certain clearances and certificates were sought within 30 days in connection with the regularization. The Company is taking steps to complete the process of submission of the sought clearances and certificates, which involves taking a number of actions, significant expenses and capital expenditure. While the Company is co-operating to get all the clearances, it has been legally advised that, as per the agreement between the Company and Fortis Health Management Limited (FHML), it is not required to bear any expenses, revenue or capital nature, incurred towards regularization of building and obtaining the requisite clearances and certificates (or for the expenses that may need to be incurred in the unlikely event that the regularization is not approved) as all such expenses will be borne by FHML. The Company also continues to believe that all Orders / Notices issued by CMDA prima facie would not result in any significant adverse impact on its financial results or on the going concern status.

B S R & Co. LLP

Limited Review Report (Continued)
Fortis Malar Hospitals Limited

Our opinion is not modified in respect of this matter.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Harsh Vardhan Lakhotia

Harsh Vardhan Lakhotia

Partner

Chennai

06 November 2023

Membership No.: 222432

UDIN:23222432BGYLCC4536

Limited Review Report on unaudited consolidated financial results of Fortis Malar Hospitals Limited for the quarter ended 30 September 2023 and year to date results for the period from 01 April 2023 to 30 September 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Fortis Malar Hospitals Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Fortis Malar Hospitals Limited (hereinafter referred to as "the Parent"), and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 30 September 2023 and year to date results for the period from 01 April 2023 to 30 September 2023 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the subsidiary company, Malar Stars Medicare Limited.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We draw attention to Note 7 to the consolidated financial results which describes the litigation and issues pertaining to regularization of the hospital building in which the Parent operates today and the related matters. A letter was received from Chennai Metropolitan Development Authority (CMDA) on 25 August 2020, wherein certain clearances and certificates were sought within 30 days in connection with the regularization. The Parent is taking steps to complete the process of submission of the sought clearances and certificates, which involves taking a number of actions, significant expenses and capital expenditure. While the Parent is co-operating to get all the clearances, it has been legally advised that, as per the agreement between the Parent and Fortis Health Management Limited (FHML), it is not required to bear any expenses, revenue or capital nature, incurred towards regularization of building and obtaining the requisite clearances and certificates (or for the expenses that may need to be incurred in the unlikely event that the regularization is not approved) as all such

B S R & Co. LLP

Limited Review Report (Continued)

Fortis Malar Hospitals Limited

expenses will be borne by FHML. The Parent also continues to believe that all Orders / Notices issued by CMDA prima facie would not result in any significant adverse impact on its financial results or on the going concern status.

Our opinion is not modified in respect of this matter.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Harsh Vardhan Lakhotia

Harsh Vardhan Lakhotia

Partner

Membership No.: 222432

UDIN:23222432BGYLCB3343

Chennai

06 November 2023